Don’t let the high cost of brand specialty XDR-TB therapy disrupt your treatment. We help eligible patients access Pretomanid (pretomanid) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
Pretomanid PAP for MDR/XDR-TB patients.
Eligibility, ID/TB clinic/public health TB program coordination.
AffordMyPrescriptions eliminates that burden. $69.95/month advocacy.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$5,500/course | Save substantially |
| CVS Pharmacy | ~$6,000/course | Save substantially |
| Walmart | ~$4,300/course | Save substantially |
| Costco | ~$4,200/course | Save substantially |
State TB program | Often free | MDR-TB programs |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
PAP at no cost. State and local TB programs typically coordinate MDR/XDR-TB therapy regardless of insurance — public health priority.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Pretomanid:
Still $4,000–$6,000 per 6-month course per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Pretomanid assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Pretomanid is a nitroimidazooxazine antimycobacterial used as part of the BPaL regimen (Bedaquiline + Pretomanid + Linezolid) for XDR-TB and treatment-intolerant or non-responsive MDR-TB. This 6-month all-oral regimen has transformed treatment of highly drug-resistant TB — vs. the older 18–24 month injectable regimens.
How Pretomanid Works:
XDR-TB resists isoniazid, rifampin, fluoroquinolones, AND injectable second-line drugs — historically very difficult to treat (cure rates 30–50%, 2 years of toxic therapy). The BPaL regimen revolutionized this: 89% cure rate at 6 months with all-oral therapy.
Pretomanid is activated by mycobacterial deazaflavin-dependent nitroreductase (Ddn) to nitric oxide and other metabolites that kill TB bacteria. Active against replicating and non-replicating M. tuberculosis. The synergistic BPaL combination targets TB at multiple metabolic steps for rapid sterilization.
Form and use:
Pretomanid 200 mg once daily by mouth, with food (food significantly increases absorption). Given as part of BPaL regimen: bedaquiline (varying schedule), pretomanid (daily x 6 months), linezolid (daily x 6 months). Total 6-month course.
Generic availability:
No generic. Pretomanid is developed by TB Alliance (non-profit). The CDC and state/local TB programs coordinate access. BPaL regimen now widely adopted for XDR-TB and treatment-intolerant MDR-TB. Variations: BPaLM (adds moxifloxacin) for some MDR-TB; ongoing research for shorter regimens.
Warnings:
Pretomanid carries warnings for hepatotoxicity (LFT monitoring required), peripheral and optic neuropathy (mainly from concurrent linezolid; monitor neurologic and visual function), myelosuppression (mainly from linezolid; CBC monitoring), QT prolongation (mainly from bedaquiline), reproductive toxicity in males (decreased fertility — counsel male patients), and rare hypersensitivity.
Pretomanid alone $4,000–$6,000 per 6-month course. Full BPaL regimen (with bedaquiline, linezolid) more expensive. State TB programs often coordinate free access for MDR/XDR-TB.
Bedaquiline + Pretomanid + Linezolid — 6-month all-oral regimen for XDR-TB and treatment-intolerant MDR-TB. ~89% cure rate vs ~30–50% historical with older regimens. Major advance for highly drug-resistant TB.
MDR/XDR-TB is a public health priority. State and local TB programs coordinate diagnosis, treatment, and directly observed therapy regardless of insurance status. Contact your state TB control program for any MDR/XDR-TB case.
Pretomanid is a CYP3A4 substrate. Major concerns: linezolid + serotonergic agents (serotonin syndrome), bedaquiline + QT-prolonging drugs. TB physician coordinates complex interactions.
Complex multi-drug regimen — peripheral neuropathy and optic neuropathy (mainly linezolid; baseline and follow-up testing), myelosuppression (CBC every 1–2 weeks), hepatotoxicity, QT prolongation, lactic acidosis (linezolid).
Limited data. Pretomanid causes male reproductive toxicity. Discuss with TB physician — TB therapy in pregnancy is complex.
State TB programs typically provide MDR/XDR-TB therapy regardless of insurance. TB Alliance access program. CDC TB program. Public health priority for access.
If facing Pretomanid cost for MDR/XDR-TB, contact state TB program immediately — public health priority. Our advocacy helps coordinate. Check eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.